Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Genetic Technologies (NASDAQ:GENE)

Aligos Therapeutics (NASDAQ:ALGS) and Genetic Technologies (NASDAQ:GENE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Institutional & Insider Ownership

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Genetic Technologies shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 6.5% of Genetic Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Aligos Therapeutics and Genetic Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$15.53 million	7.92	-$87.68 million	($13.32)	-2.57
Genetic Technologies	$7.66 million	0.44	-$7.88 million	N/A	N/A

Genetic Technologies has lower revenue, but higher earnings than Aligos Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for Aligos Therapeutics and Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0	0	1	0	3.00
Genetic Technologies	0	0	0	0	0.00

Aligos Therapeutics presently has a consensus target price of $75.00, indicating a potential upside of 119.04%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Aligos Therapeutics is more favorable than Genetic Technologies.

Profitability

This table compares Aligos Therapeutics and Genetic Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%
Genetic Technologies	N/A	N/A	N/A

Risk and Volatility

Aligos Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Genetic Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Summary

Aligos Therapeutics beats Genetic Technologies on 8 of the 12 factors compared between the two stocks.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.